In a new randomized controlled trial, both aerobic and resistance exercise improved glycemic/blood sugar control in people with type 2 diabetes. The greatest improvements came from combined aerobic and resistance training.
Two U.S. Department of Health and Human Services agencies will collaborate in the most comprehensive study to date of prescription medications used to treat attention deficit hyperactivity disorder (ADHD) and the potential for increased risk of heart attack, stroke or other cardiovascular problems.
Air pollution could be putting patients with heart disease at risk by affecting blood vessels and clotting, researchers warn. A study by the University of Edinburgh and Umeå University measured the effects of diesel exhaust on heart and blood vessel function in men who have previously experienced a heart attack.
GlaxoSmithKline (NYSE: GSK) believes that conclusions drawn from the most recent meta-analyses published by Drs. Nissen et. al. and Furberg et. al. in the Journal of the American Medical Association (JAMA) do not confirm a difference in the safety profile of Avandia (rosiglitazone) and Actos (pioglitazone).
A network meta-analysis of 38 randomized controlled trials encompassing more than 18,000 patients found that the mortality risks associated with drug-eluting stents and bare-metal stents are similarly low. This analysis, the largest of its kind to date comparing drug-eluting stents (the CYPHER® Sirolimus-eluting Coronary Stent and the Taxus Stent) to bare-metal stents, appears this week in the medical journal The Lancet.
More than 20 million adults in the United States are living with diabetes and are at increased risk of cardiovascular disease (CVD). But there are steps that they can take to reduce the complications associated with these two diseases.
A new book of pocket-charts that will help health workers to identify people at risk of heart attacks and strokes and save lives by prescribing the most appropriate treatment is published by the World Health Organization (WHO).
Patients with end-stage kidney disease treated with high doses of folic acid and B vitamins to lower homocysteine levels did not have improvement in survival or reductions in the incidence of vascular events, according to a study in the Sept. 12 issue of JAMA.
An analysis of four studies involving more than 14,000 patients found that long-term use of the diabetes drug rosiglitazone (Avandia) increased the risk of heart attack by 42 percent and doubled the risk of heart failure, according to a new report from researchers at Wake Forest University School of Medicine and colleagues. There was no effect on death from cardiovascular causes.
Takeda Pharmaceuticals North America, Inc. is aware of the review of ACTOS (pioglitazone HCl) data conducted by A. Michael Lincoff, M.D., and colleagues at the Cleveland Clinic, published in the Journal of the American Medical Association, which concluded that ACTOS is associated with a significantly lower risk of heart attack, stroke or death among a diverse population of 16,390 patients with diabetes versus control therapy.